TITLE

Recently Approved

PUB. DATE
April 2007
SOURCE
Pharmaceutical Representative;Apr2007, Vol. 37 Issue 4, p14
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents various drugs recently approved by the U.S. Food and Drug Administration. The once-daily formulation of cyclobenzaprine Amrix extended-release capsules of ECR Pharmaceuticals Inc., has been approved for use as an adjunct to rest and physical therapy. The drug Cymbalta by Eli Lilly & Co. is now indicated for the treatment of generalized anxiety disorder. A marketing authorization for Biochimique SA's Flector Patch has been given for the topical treatment of acute pain.
ACCESSION #
24619971

 

Related Articles

  • Eli Lilly: Cymbalta approved for treatment of anxiety.  // PharmaWatch: CNS;Apr2007, Vol. 6 Issue 4, p9 

    The article reports on the approval of Eli Lilly's Cymbalta, a serotonin and norepinephrine reuptake inhibitor for the treatment of patients with generalized anxiety disorder (GAD), by the U.S. Food and Drug Administration. Cymbalta is a class of drugs that is primarily indicated for the...

  • Zyprexa era comes to an end for Lilly as generic versions begin.  // Indianapolis Business Journal;10/31/2011, Vol. 32 Issue 35, p13A 

    The article reports on the approval of Eli Lilly & Co.'s antipsychotic medication, Zyprexa, by the U.S. Food and Drug Administration (FDA) in 2011.

  • FDA signs off on manufacturing operations. Maurer, Katie // Indianapolis Business Journal;11/10/2003, Vol. 24 Issue 35, p37 

    Reports that the U.S. Food and Drug Administration has cleared Eli Lilly and Co. of manufacturing problems at two Indianapolis plants in Indiana. Approval of drugs; Availability of drugs.

  • ELI LILLY. Investor's Business Daily // Investors Business Daily;4/22/2014, pA02 

    The article reports on the U.S. Food and Drug Administration's (FDA) approval of the ramucirumab advanced stomach cancer drug from pharmaceutical firm Eli Lilly & Co.

  • Advances in Diabetes Medications Continue.  // Chain Drug Review;3/16/2015, Vol. 37 Issue 5, p82 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the launch of the Glyxambi drug for type 2 diabetes patients from Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals Inc.

  • Lilly gets a string of small victories.  // Indianapolis Business Journal;11/22/2010, Vol. 31 Issue 38, p13A 

    The article reports on the drug approval of Eli Lilly and Co.'s antidepressant Cymbalta to treat chronic pain by the Food and Drug Administration's (FDA) in the U.S.

  • Eli Lilly: Cymbalta approved for treatment of anxiety.  // PharmaWatch: Monthly Review;Apr2007, Vol. 6 Issue 4, p15 

    The article presents information on an approval by the U.S. Food and Drug Administration (FDA) to Eli Lilly & Co.'s Cymbalta to treat patients with generalized anxiety disorder (GAD). It is stated that Cymbalta, a seroronin and norepinephrine reuptake inhibitor, is already approved in the U.S....

  • LILLY'S NEW LOVE DRUG. Kaelble, Steve // Indiana Business Magazine;Dec2003, Vol. 47 Issue 12, p8 

    Discusses the approval of the U.S. Food and Drug Administration the sale of Eli Lilly & Co.'s Cialis, the drug maker's answer to Viagra. Viagra sales in 2002; Comparison between Viagra and Cialis in terms of speed and duration; Advertising campaign for Cialis.

  • Lilly ICOS: Cialis third to tango.  // PharmaWatch: CNS;January 2004, Vol. 3 Issue 1, p15 

    Reports that the United States Food and Drug Administration has approved Lilly Icos LLC's Cialis for erectile dysfunction treatment. Advantages of Cialis over other drugs; Estimated number of men with erectile dysfunction worldwide; Competitors of Lilly.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics